Lisa M. DeAngelis, MSKCC

MSK picks brain can­cer ex­pert Lisa DeAn­ge­lis as its next CMO — fol­low­ing José Basel­ga’s con­tro­ver­sial ex­it

It’s of­fi­cial. Memo­r­i­al Sloan Ket­ter­ing has picked a brain can­cer ex­pert as its new physi­cian-in-chief and CMO, re­plac­ing José Basel­ga, who left un­der a cloud af­ter be­ing sin­gled out by The New York Times and ProP­ub­li­ca for fail­ing to prop­er­ly air his lu­cra­tive in­dus­try ties.

His re­place­ment, who now will be in charge of MSK’s cut­ting-edge re­search work as well as the can­cer care de­liv­ered by hun­dreds of prac­ti­tion­ers, is Lisa M. DeAn­ge­lis. DeAn­ge­lis had been chair of the neu­rol­o­gy de­part­ment and co-founder of MSK’s brain tu­mor cen­ter and was moved in to the act­ing CMO role in the wake of Basel­ga’s de­par­ture.

The Times cov­er­age not­ed that DeAn­ge­lis sought to as­sure staffers that MSK rec­og­nized their con­cerns, but added that she was quick to high­light any up­beat news about their ac­com­plish­ments, in­clud­ing the ap­proval of Vi­t­rakvi — which they played a role in — and their han­dling of Supreme Court Jus­tice Ruth Bad­er Gins­burg’s can­cer care.

Craig Thomp­son MSKCC

“Her ex­per­tise and unique un­der­stand­ing of MSK’s mis­sion make her the ide­al per­son to lead MSK’s clin­i­cal en­ter­prise in­to the fu­ture,” said MSK CEO Craig Thomp­son in a state­ment.

It al­so se­cures a promi­nent po­si­tion at one of the most high-pro­file re­search cen­ters in the world, where in­ves­ti­ga­tors have played a big role in the rapid­ly evolv­ing world of can­cer drug re­search.

Al­most ex­act­ly a year ago, Basel­ga was swept up in con­tro­ver­sy when The Times pub­lished a sto­ry out­lin­ing fre­quent cas­es when he ig­nored list­ing his ex­ten­sive ties to the bio­phar­ma in­dus­try. Soon af­ter the sto­ry hit he bowed out of MSK as well as the board of Bris­tol-My­ers Squibb, and then a few months lat­er was back as the new can­cer R&D chief at As­traZeneca, which has been mak­ing ma­jor strides with its on­col­o­gy group. 

Though con­tro­ver­sial at the time, Basel­ga al­so re­ceived con­sid­er­able sup­port for his stance that he hadn’t in­tend­ed to de­ceive any­one, and of­ten de­light­ed in dis­cussing the same high-pro­file ties that he ne­glect­ed to list when nec­es­sary. As for MSK, the em­bar­rass­ment of be­ing in the crosshairs of The Times trig­gered a wide-rang­ing in­ves­ti­ga­tion, which de­ter­mined that many of its re­searchers had done the same. And the aca­d­e­m­ic re­search cen­ter adopt­ed new rules bar­ring top ex­ecs from sit­ting on the boards of for-prof­it com­pa­nies.

That led Thomp­son to cut his ties to Mer­ck’s board, which paid about $300,000 a year.

DeAn­ge­lis will have plen­ty to do with­out the high-lev­el in­dus­try ties that once came with her po­si­tion.

UP­DAT­ED: Mer­ck pulls Keytru­da in SCLC af­ter ac­cel­er­at­ed nod. Is the FDA get­ting tough on drug­mak­ers that don't hit their marks?

In what could be an early shot in the battle against drugmakers that whiff on confirmatory studies to support accelerated approvals, the FDA ordered Bristol Myers Squibb late last year to give up Opdivo’s approval in SCLC. Now, Merck is next on the firing line — are we seeing the FDA buckling down on post-marketing offenders?

Merck has withdrawn its marketing approval for PD-(L)1 inhibitor Keytruda in metastatic small cell lung cancer as part of what it describes as an “industry-wide evaluation” by the FDA of drugs that do not meet the post-marketing checkpoints on which their accelerated nods were based, the company said Monday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,400+ biopharma pros reading Endpoints daily — and it's free.

The 2021 top 100 bio­phar­ma in­vestors: As the pan­dem­ic hit and IPOs boomed, VCs swung in­to ac­tion like nev­er be­fore

The global pandemic may have roiled economies, killed hundreds of thousands and throttled entire industries, but the only effect it had on biopharma venture investing was to help turbocharge the field to giddy new heights.

Below you’ll find the new top 100 venture investors in the industry, ranked by the number of deals they were publicly involved in, as tracked by DealForma chief Chris Dokomajilar. The numbers master then calculated the estimated amount of money they put into each deal — divvying up the cash by the number of players — to indicate how they managed their syndicates.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Hal Barron, Endpoints UKBIO19

GSK, Vir's hopes for a Covid-19 an­ti­body fall flat in NIH 'mas­ter pro­to­col' with no ben­e­fit in hos­pi­tal­ized pa­tients

GlaxoSmithKline and Vir Biotechnology were hopeful that one of their partnered antibodies would carve out a win after getting the invite to a major NIH study in hospitalized Covid-19 patients. But just like Eli Lilly, the pair’s drug couldn’t hit the mark, and now they’ll be left to take a hard look at the game plan.

The NIH has shut down enrollment for GSK and Vir’s antibody VIR-7831 in its late-stage ACTIV-3 trial after the drug showed negligible effect in achieving sustained recovery in hospitalized Covid-19 patients, the partners said Wednesday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,400+ biopharma pros reading Endpoints daily — and it's free.

As Brain­Storm con­tin­ues to tout ‘clear sig­nal’ on ALS drug, the FDA of­fers a rare pub­lic slap­down on the da­ta

A little more than a week after BrainStorm acknowledged that regulators at the FDA had informed them that the biotech needed more data before it could expect to gain an approval for its ALS treatment NurOwn — while still touting a “clear signal” of efficacy and not ruling out an application — the agency has decided to clarify the record in a most unusual statement.

The FDA statement amounts to a straight slap own, offering a different set of efficacy numbers from the company’s public presentation last November and ruling out any chance of statistical significance.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,400+ biopharma pros reading Endpoints daily — and it's free.

Eli Lil­ly claims suc­cess in a new JAK in­di­ca­tion: hair loss

Over the last decade, drugmakers have proven JAK inhibitors can treat a smattering of immune-related diseases ranging from rheumatoid arthritis to Covid-19. Now Eli Lilly has pulled out a new one.

Lilly and its biotech partner Incyte announced Wednesday that their JAK inhibitor baricitinib effectively regrew patients’ hair in a Phase III trial for alopecia areata, an autoimmune condition that can cause sudden, severe and patchy hair loss. Lilly didn’t break down the results from the 546-patient trial, but the primary endpoint was improvement on a standard score for alopecia symptoms.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,400+ biopharma pros reading Endpoints daily — and it's free.

In­tro­duc­ing End­points FDA+, our new pre­mi­um week­ly reg­u­la­to­ry news re­port led by Zachary Bren­nan

CRLs. 483s. CBER, CDER and RWE. For biopharma professionals, these acronyms command attention because of the fundamental role FDA plays in drug development. Now Endpoints is doubling down on regulatory coverage, and launching a weekly report focusing on developments out of White Oak, with analysis and insight into what it all means.

Coverage will be led by our new senior editor, Zachary Brennan. He joins Endpoints from POLITICO, where he covered pharma. Prior to that he was the managing editor for Regulatory Focus, a news publication from the Regulatory Affairs Professionals Society.

Thank you, next: Take­da hands Ovid $196M cash to rein back in Phase III-ready seizure drug, re­viv­ing bat­tered stock

Soticlestat made it.

Takeda is bringing the drug back into its fold more than four years after first entrusting the team at Ovid with the mid-stage clinical work. For all that — generating what they saw as positive Phase II data in Dravet syndrome and Lennox-Gastaut syndrome — the biotech has been rewarded with $196 million in upfront cash, with another $660 million reserved for regulatory and commercial milestones.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 102,400+ biopharma pros reading Endpoints daily — and it's free.

Michael Shpigelmacher

Khosla joins bet on un­con­ven­tion­al start­up look­ing to send drug de­liv­er­ing ro­bots in­to the brain

When Michael Shpigelmacher started the project, he knew he’d have to fund it himself. Every other effort of its kind was academic, rejected as too risky by investors.

Shpigelmacher, a robotics geek and entrepreneur who had drifted into consulting for pharma, wanted to build the real-life equivalent of technology from the 1960s film “Fantastic Voyage,” the one where a submarine crew is shrunk to “about the size of a microbe” and sent on a mission to repair a scientist’s brain. He scanned the literature, found the lab that was working on the most advanced project — at the Max Planck Institute in Germany, it turned out — and started funding them with money from his and his co-founders’ own accounts, along with some seed cash from friends and family.

Antoine Papiernik, Sofinnova managing director (Business Wire)

Sofinno­va Part­ners stays fo­cused on late-stage deals with a new, $540M crossover fund

One of Europe’s most high-profile biopharma investors is getting $540 million to invest in new crossover deals for late-stage companies.

The Paris-based VC says the fresh Sofinnova Crossover Fund raise positions them as the “largest crossover investor in Europe dedicated to late-stage biopharma and medtech investments.”

They got a leg up in France after winning a special “Tibi” designation from the French government, giving them access to a pool of €6 billion that helped them gain an edge with institutional investors. Since they were founded close to 50 years ago, the venture group has backed more than 500 companies and currently has more than €2 billion under management.